Southern Glazer's Wine & Spirits Announces Expanded Distribution With Bogle Family Wine Collection in California
Southern Glazer's announced the expansion of its distribution agreement with Bogle Family Wine Collection to California, effective September 1, 2025.
Warren Bogle, President of Bogle Family Wine Collection, highlights the importance of partnering with a distributor that exemplifies world-class service and aligns with strategic goals. 'As a family-owned operation, choosing a distributor that shares our values in quality winemaking and sustainability is crucial. Southern Glazer's is the right fit to ensure our brands thrive in California and resonate with new customers,' he stated.
Southern Glazer's stands out in the marketplace by equipping its people with an unmatched suite of tools, training, and resources to deliver the most personalized, best-in-class service and solutions in the industry. The Company's expert advisors connect suppliers with essential consumer insights, industry expertise, retail access, and dependable logistics—empowering brands to grow faster, smarter, and better. The Company's proprietary Proof® e-commerce platform exemplifies its focus on customer experience, enabling seamless engagement for retailers, ensuring that Bogle Family Wine Collection products are both accessible and effectively promoted.
Adding to its enterprise capabilities, in California alone, Southern Glazer's boasts a dedicated team of more than 1,200 sales resources, including a large group of specialists focused on statewide hotel accounts. These specialists, highly educated in wine and spirits, cover major independent and national hotels, with the local autonomy necessary to secure market share and optimize programming across various revenue sources, such as restaurants, poolside services, in-room dining, banquets, and grab-and-go options. Additionally, Southern Glazer's of California has a dedicated regional on and off-premise account team that calls on over 100 multi-unit buyers.
The extensive expertise within the salesforce in California is further highlighted by nearly 1,700 advanced certifications in wine and spirits, including 31 certified sommeliers, ensuring that Bogle wines are presented in a way that fosters loyalty and deepens consumer understanding. Southern Glazer's also supports national off-premise chains supported with dedicated vertical headquarters teams and field merchandising teams comprising more than 1,000 merchandisers.
Wayne E. Chaplin, President and Chief Executive Officer of Southern Glazer's, expressed enthusiasm for this partnership: 'We are excited to elevate our relationship with Bogle Family Wine Collection in California, the nation's most dynamic beverage alcohol market. Our longstanding trust ensures that our combined efforts will yield extraordinary results."
Both companies remain committed to ensuring that Bogle Family Wine Collection maintains a strong presence in California's competitive landscape while enhancing consumer awareness of their commitment to sustainable winemaking practices.
About Southern Glazer's Wine & Spirits
Southern Glazer's Wine & Spirits is the world's preeminent distributor of beverage alcohol, building brands for moments that matter. The multi-generational, family-owned Company has operations in 47 U.S. markets and Canada, as well as brokerage operations through its Southern Glazer's Travel Retail Sales & Export Division in the Caribbean, Central and South America. In 2025, Southern Glazer's was recognized by Newsweek as one of America's Greatest Workplaces for Diversity and America's Greatest Workplaces for Women. Southern Glazer's urges all retail customers and adult consumers to market, sell, serve, and enjoy its products responsibly. For more information visit www.southernglazers.com. Follow us on Facebook, X and Instagram @sgwinespirits.
About Bogle Family Wine Collection
Bogle Family Wine Collection is headquartered in Clarksburg, California, and is run by the sixth generation of the Bogle family to live and work in the Sacramento Delta region. The Bogle family began growing winegrapes in 1968 and first bottled wine under the name Bogle Vineyards in the late 1970s. Bogle was honored as Wine Enthusiast's 2019 American Winery of the Year and was presented with the Green Medal Leader Award in 2018 for its sustainability efforts in the winery and vineyards. The Bogle Family Wine Collection includes Bogle Family Vineyards, Juggernaut Wines, Phantom Wines, TWENTY ACRES by Bogle and the latest release – Element[AL], which features ground-breaking aluminum wine bottle packaging.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 minutes ago
- Business Wire
ISG to Study Healthcare Digital Service Providers
STAMFORD, Conn.--(BUSINESS WIRE)--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining healthcare digital service providers' capabilities to upgrade client technologies and build agile frameworks, with a focus on innovation and resilience. Healthcare adoption of digital solutions is critical for addressing challenges and enhancing patient engagement. Through integration of innovative technologies, providers can improve system efficiency while maintaining data security as regulations evolve. The study results will be published in a series of comprehensive ISG Provider Lens ® reports, called Healthcare Digital Services, scheduled to be released in December 2025. The reports will cover companies offering services for payer and provider digital transformation, value-based care and data security. Enterprise buyers will be able to use information from the reports to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm's buy-side clients. Digital transformation is becoming a strategic imperative for healthcare companies, many of which are adopting AI, telemedicine, and wearable technologies to improve patient care and operational efficiency. AI has enhanced diagnostics and personalized treatment, while secure telemedicine broadens access to expert care. Wearable devices are opening the door to proactive health management with real-time monitoring. Despite interoperability challenges and cyber threats, these trends are driving ongoing improvements in healthcare accessibility and efficiency. 'Healthcare enterprise adoption of digital solutions is critical for addressing industry challenges and enhancing patient engagement,' said Iain Fisher, director at ISG. 'Through strategic integration of innovative technologies, providers can improve system efficiency while maintaining data security as regulations evolve.' ISG has distributed surveys to more than 150 healthcare digital services providers. Working in collaboration with ISG's global advisors, the research team will produce four quadrants representing the digital services typical healthcare enterprises are buying, based on ISG's experience working with its clients. The four quadrants are: Payer Digital Transformation, evaluating providers offering digital transformation services to healthcare payers, including insurers, coverage firms and managed care organizations. Their key services include automating claims, eligibility and authorizations and using AI for risk prediction, fraud detection and personalized engagement. Provider Digital Transformation, assessing providers delivering digital transformation services to healthcare organizations, including hospitals, clinics and integrated care networks. The providers are assessed on their ability to integrate digital technologies, including IoT-enabled medical devices and data analytics for modernizing healthcare systems efficiently. Value-Based Care, covering providers offering services that support value-based care in hospitals, physician groups and accountable care organizations. They integrate electronic health records, real-time analytics, patient engagement platforms and care coordination tools for continuous outcome measurement and tailored interventions. Interoperability and Data Security, evaluating providers offering interoperability and data security services to healthcare centers, including hospitals, clinics, payers and partners. The providers are assessed on their ability to facilitate seamless data exchange across platforms, implement modern security measures and maintain continuous threat surveillance. Geographically focused reports from the study will cover the global healthcare digital services market and examine products and services available in the U.S. and Brazil. ISG analysts Rohan Sinha (U.S.) and Sonia Castral (Brazil) will serve as authors of the reports. A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as healthcare digital service providers can contact ISG and ask to be included in the study. All 2025 ISG Provider Lens ® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG's continuous CX research. Enterprise customers wishing to share their experience about a specific provider or vendor are encouraged complete this online survey. Participants will receive a copy of this report in return for their feedback. About ISG Provider Lens ® Research The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Business Wire
10 minutes ago
- Business Wire
AI-Powered Software Is Solving the E-Payments Dilemma: The Hackett Group
MIAMI--(BUSINESS WIRE)-- The Hackett Group, Inc. (NASDAQ: HCKT), a leading generative artificial intelligence (Gen AI) consultancy and executive advisory firm, has released its latest Digital World Class ® Matrix, focusing on the cash application software marketplace. The report reveals leading vendor capabilities in the space and examines the critical relationship between AI-powered touchless invoice-level payment matching and improved cash flow. Our analysis highlights the correlation of increased cash application match rates with the ability to liberate up to $15M in unapplied cash to business operations. These factors create a compelling business case for investing in cash application software. Share Cash application process software can deliver rewards in terms of both cost and cash, with cash flow and working capital being significantly highlighted. In The Hackett Group's 2025 Finance Key Issues Study published earlier this year, optimizing cash flow performance has become the No. 1 chief financial officer (CFO) priority. Automating the cash application process has a transformational impact on finance organizations struggling with low transaction match rates. It enables a 63% reallocation of staff and a 43% decrease in process cost across receivables management functions, including cash application, collections, and dispute management – critical efficiencies as finance leaders continue to be challenged to do more with less. Congruently, these leaders are also being tasked with delivering critical operating cash flow to the business. Our analysis highlights the correlation of increased cash application match rates with the ability to liberate up to $15M in unapplied cash to business operations. These factors create a compelling business case for investing in modern cash application software. The Cash Application Software Digital World Class ® Matrix provides a guide to the leading software vendors and their impact on companies' customer-to-cash processes. These tools accurately match customer payments and remittance advice with open invoices, automatically account for short payments, generate workflow for unearned deductions, and accelerate the availability of operating cash. The report evaluated 15 vendors that offer cash application software for their capabilities and the value delivered to clients based on vendor briefings and customer data input across 16 different criteria. Capability ratings assess a vendor's capacity to integrate with enterprise resource planning (ERP) systems, receivables management tools, banks, and payment portals to intelligently capture data and match payments with open invoices. They also evaluate whether the solution delivers this functionality through an intuitive, user-friendly interface, and provides real-time performance dashboards. Value realization ratings measure vendors' impact on key cash application process performance metrics such as the touchless automated match rate, remittance-less match rates, application cycle times and the reduction of unapplied cash. Among end users assessed, the median auto-match rate is 70% with a third of end users achieving match rates exceeding 80%, 61% are matching payments on the same day they are received, and 51% of end users indicated their software is delivering remittance-less match rates for up to 60% of their cash application volume. User adoption and overall satisfaction with the software were both exceptionally high at 91%. All vendors have predictive AI and machine learning functionality in their platforms, and that technology continues to mature. Gen AI is being developed and deployed to specifically address the challenges of short payments and unearned deductions. Gen AI is initiating the necessary internal and external communications related to unearned deductions and supporting resolution workflows. 'With improvement of cash flow and working capital being the top priority for CFOs, every process that involves cash must be evaluated and optimized,' said Bryan DeGraw, associate principal and senior research director for Finance Market Intelligence at The Hackett Group ®. 'A surprising number of organizations are accepting automation rates below 40%, taking up to three days to post payments, and carrying up to 6% of unapplied cash. This lack of competitive performance in a back-office process like cash application can significantly impact an organization's ability to be agile and compete in its respective markets. The cash flow benefits of AI-powered cash application software can be quickly realized through average implementations of three to six months. Immediate benefits can evolve to significant long-term cost savings and improved cash flow for organizations growing organically or through acquisitions.' By using this comprehensive analysis, professionals and leaders in finance and global business services can make informed purchasing decisions aligned with their strategic priorities and critical performance metrics through improved process cost, cash flow, and customer experience. Cash Application Software Digital World Class ® assessments are part of The Hackett Group's full 62-page report. The assessments should be read in the context of the entire report. Download a complimentary summary of the cash application software research with registration. Contact us for inquiries about purchasing the full research report. The Hackett Group ® does not endorse any participant, vendor, product or service depicted in its research. This research should not be considered as advice that a buyer select only those participants based on their ranking or position on The Hackett Group's Digital World Class ® Matrix. You should not rely upon any material or information within this research as a basis for making any business, legal, financial or any other decisions. Any such reliance shall be solely at buyer's risk. The Hackett Group research publications consist of the opinions of its research organization and should not be interpreted as factual statements. To the fullest extent permitted by law, The Hackett Group ® disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability, suitability or fitness for a particular purpose. The information contained in this research is provided on an 'as-is' basis with no guarantees of completeness, accuracy, usefulness or timeliness. The Hackett Group ® assumes no responsibility or liability for damages of any kind arising from any information, data, content, materials, or references within its research, including but not limited to direct, indirect, incidental, consequential, special, and punitive damages. About The Hackett Group ® The Hackett Group, Inc. (NASDAQ: HCKT) is an IP and platform-based, Gen AI strategic consulting and executive advisory firm that enables Digital World Class® performance. Using AI XPLR™ and ZBrain™ – our ideation through implementation platforms – our experienced professionals help organizations realize the power of Gen AI and achieve quantifiable, breakthrough results, allowing us to be key architects of their Gen AI journey. Our expertise is grounded in unparalleled best practices insights from benchmarking the world's leading businesses – including 97% of the Dow Jones Industrials, 90% of the Fortune 100, 70% of the DAX 40 and 51% of the FTSE 100. Visit us at Trademarks The Hackett Group ®, quadrant logo, and Digital World Class ® are the registered marks of The Hackett Group ®. Cautionary Statement Regarding 'Forward-Looking' Statements This release contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements including without limitation, words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' or other similar phrases or variations of such words or similar expressions indicating, present or future anticipated or expected occurrences or outcomes are intended to identify such forward-looking statements. Forward-looking statements are not statements of historical fact and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that may impact such forward-looking statements include without limitation, the ability of The Hackett Group ® to effectively market its digital transformation, our ability to transition our capabilities to support generative artificial intelligence (AI)-related consulting services and solutions and other consulting services, our ability to effectively integrate acquisitions into our operations, our ability to manage joint ventures and successfully cooperate with our joint venture partners, competition from other consulting and technology companies that may have or develop in the future, similar offerings, the commercial viability of The Hackett Group ® and its services as well as other risk detailed in The Hackett Group's reports filed with the United States Securities and Exchange Commission. The Hackett Group ® does not undertake any duty to update this release or any forward-looking statements contained herein.
Yahoo
33 minutes ago
- Yahoo
PharmaTher Announces FDA Approval of Ketamine (KETARx™)
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the 'Company' or 'PharmaTher') (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company's ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards mental health, neurological, and pain disorders. Fabio Chianelli, Founder, Chairman and CEO of PharmaTher, commented: 'Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signalling a new era of growth. We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders.' Ketamine stands out among psychedelic and psychedelic-adjacent drugs as the only one included on the World Health Organization's Model List of Essential Medicines1. The global ketamine market is expected to experience substantial growth, currently valued at $750 million and projected to reach $3.42 billion by 2034, indicating a compound annual growth rate of 16.4%2. Furthermore, SPRAVATO® (esketamine), an FDA approved treatment for depression, is tracking a sales run rate of $1.6 billion, with guidance anticipating $3 billion to $3.5 billion by 2027-20283. This promising market outlook underscores the potential of KETARx™ and PharmaTher's strategic position in the industry. The FDA's approval of the Company's ketamine product, KETARx™, provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas within the Company's product pipeline. These areas include mental health conditions like depression, neurological disorders such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS), and the management of rare or chronic pain, including Complex Regional Pain Syndrome (CRPS). Since February 2018, ketamine has been regularly listed on the FDA drug shortage list, highlighting a significant need for a consistent, high-quality supply. This issue is cautioned by a compounding risk alert issued by the FDA on October 10, 20234, which detailed potential risks associated with compounded ketamine products used for psychiatric disorders. Robert F. Kennedy Jr., Secretary of Health and Human Services, has also emphasized the importance of expanding research and ensuring legal access to psychedelic therapies for veterans5. The Veterans Health Administration, the largest integrated healthcare system in the U.S., currently approves and funds ketamine infusions for retired military personnel afflicted with depression, PTSD, and chronic pain6. Furthermore, FDA Commissioner Marty Makary's establishment of the Commissioner's National Priority Voucher program signifies the FDA's dedication to expediting access to safe and effective treatments, instilling confidence in potential future regulatory support and accessibility for ketamine. About PharmaTher Holdings Ltd. PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on unlocking the pharmaceutical potential of Ketamine (KETARx™) for mental health, neurological, and pain disorders. For more information, visit For more information about PharmaTher, please contact:Fabio ChianelliChief Executive OfficerPharmaTher Holdings 1-888-846-3171Email: info@ Website: Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words 'closer', "could", 'confident', "would", "intend", "expect", "believe", "will", "projected", "estimated", "potential", 'promise', 'strong', "aim", 'may', 'plan', 'proposed', 'lead', 'toward', 'anticipate', 'provide', 'position', 'leverage', 'mitigate', 'before', 'prior', and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the "Company") current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the three and nine months ended February 28, 2025 dated April 24, 2025, which is available on the Company's profile at This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or
